Literature DB >> 12684537

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

M C Strain1, H F Günthard, D V Havlir, C C Ignacio, D M Smith, A J Leigh-Brown, T R Macaranas, R Y Lam, O A Daly, M Fischer, M Opravil, H Levine, L Bacheler, C A Spina, D D Richman, J K Wong.   

Abstract

Viral replication and latently infected cellular reservoirs persist in HIV-infected patients achieving undetectable plasma virus levels with potent antiretroviral therapy. We exploited a predictable drug resistance mutation in the HIV reverse transcriptase to label and track cells infected during defined intervals of treatment and to identify cells replenished by ongoing replication. Decay rates of subsets of latently HIV-infected cells paradoxically decreased with time since establishment, reflecting heterogeneous lymphocyte activation and clearance. Residual low-level replication can replenish cellular reservoirs; however, it does not account for prolonged clearance rates in patients without detectable viremia. In patients receiving potent antiretroviral therapy, the latent pool has a heterogeneous and dynamic composition that comprises a progressively increasing proportion of stable lymphocytes. Eradication will not be achieved with complete inhibition of viral replication alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684537      PMCID: PMC153639          DOI: 10.1073/pnas.0736332100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study.

Authors:  M Opravil; R W Cone; M Fischer; P L Vernazza; S Bassetti; P Lorenzi; L R Bisset; P Ott; W Huber; M C Knuchel; M Roos; R Lüthy; R Weber
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

Review 2.  Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

Authors:  T Pierson; J McArthur; R F Siliciano
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis.

Authors:  W S Hlavacek; C Wofsy; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.

Authors:  T Pierson; T L Hoffman; J Blankson; D Finzi; K Chadwick; J B Margolick; C Buck; J D Siliciano; R W Doms; R F Siliciano
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells.

Authors:  C Christopherson; Y Kidane; B Conway; J Krowka; H Sheppard; S Kwok
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

6.  Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.

Authors:  S Taylor; R P van Heeswijk; R M Hoetelmans; J Workman; S M Drake; D J White; D Pillay
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

7.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

Authors:  R T Davey; N Bhat; C Yoder; T W Chun; J A Metcalf; R Dewar; V Natarajan; R A Lempicki; J W Adelsberger; K D Miller; J A Kovacs; M A Polis; R E Walker; J Falloon; H Masur; D Gee; M Baseler; D S Dimitrov; A S Fauci; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

8.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

9.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

Authors:  G Dornadula; H Zhang; B VanUitert; J Stern; L Livornese; M J Ingerman; J Witek; R J Kedanis; J Natkin; J DeSimone; R J Pomerantz
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

10.  Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Authors:  N K Back; M Nijhuis; W Keulen; C A Boucher; B O Oude Essink; A B van Kuilenburg; A H van Gennip; B Berkhout
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

View more
  118 in total

1.  Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.

Authors:  Yefei Han; Kara Lassen; Daphne Monie; Ahmad R Sedaghat; Shino Shimoji; Xiao Liu; Theodore C Pierson; Joseph B Margolick; Robert F Siliciano; Janet D Siliciano
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.

Authors:  Magdalena Magierowska; Flavien Bernardin; Seema Garg; Silvija Staprans; Michael D Miller; Koen K A Van Rompay; Eric L Delwart
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 3.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

4.  Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.

Authors:  Ingrid A Beck; Minyoung Jang; Jennifer McKernan-Mullin; Marta Bull; Thor Wagner; Sharon Huang; Lin-Ye Song; Sharon Nachman; Paul Krogstad; Susan H Eshleman; Andrew Wiznia; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2012-01-27       Impact factor: 2.205

5.  Combinatorial latency reactivation for HIV-1 subtypes and variants.

Authors:  John C Burnett; Kwang-Il Lim; Arash Calafi; John J Rossi; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

6.  Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.

Authors:  Hao Yin; Yuhao Zhang; Xin Zhou; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2010-12-23       Impact factor: 2.316

7.  Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.

Authors:  Kazuo Suzuki; Takaomi Ishida; Makoto Yamagishi; Chantelle Ahlenstiel; Sanjay Swaminathan; Katharine Marks; Daniel Murray; Erin M McCartney; Michael R Beard; Marina Alexander; Damian F J Purcell; David A Cooper; Toshiki Watanabe; Anthony D Kelleher
Journal:  RNA Biol       Date:  2011-11-01       Impact factor: 4.652

8.  Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.

Authors:  Nancie M Archin; Naveen K Vaidya; Joann D Kuruc; Abigail L Liberty; Ann Wiegand; Mary F Kearney; Myron S Cohen; John M Coffin; Ronald J Bosch; Cynthia L Gay; Joseph J Eron; David M Margolis; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

9.  Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.

Authors:  David Palesch; Steven E Bosinger; Maud Mavigner; James M Billingsley; Cameron Mattingly; Diane G Carnathan; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Guido Silvestri
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

10.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.